Medivir rights issue fully subscribed

Medivir has executed a new share issue directed preferentially to existing shareholders. The new share issue was completed on 2nd February 2007 and raised a great deal of public interest. The share issue, inclusive of non-preferential subscriptions, was fully subscribed, with 99.3% of the shares issued relying on preferential rights, meaning that non-preferential subscription has been at a very low level.

The new share issue has increased the number of shares by 7 741 566 B shares, and therefore the post-issue total is 660 000 A class shares and 19 984 177 B class shares.

The new shares are estimated to be tradable on the Nordic list of the Stockholm Stock Exchange from 28th February 2007.

The new share issue has raised around SEK 224.5 million for the company, before issue costs.

Financial advisors to Medivir in relation to the share issue was Carnegie Investment Bank

Rein Piir, CFO & VP, Investor Relations, Medivir AB +46 708 53 72 92

For more information about Medivir, please see the Medivir website:

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links